Articles
07.06.2022
EU Joint HTA: What’s going on and what does it m...

EUnetHTA and the EU Joint HTA Process Originally set up in 2006, EUnetHTA was established to facilit...

Read more
Insider Insights
26.05.2022
G-BA awards highest rating to Trodelvy

The drug was judged to offer an indication of major additional benefit in adult patients with advanc...

Read more
Articles
25.05.2022
Is Saudi Arabia the indicator for change in the Mi...

Introduction For some manufacturers, launching in the Middle East and North Africa (MENA) is fraught...

Read more
Insider Insights
20.05.2022
Improving market access for new drugs

With respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...

Read more
News
18.05.2022
PMA Insights: Week 20

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
11.05.2022
How are countries in South-East Asia establishing ...

Introduction Health Technology Assessment (HTA) implementation has been historically slow in Asia co...

Read more
04.05.2022
PMA Insights: Week 18

A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about: Regulat...

Read more
Articles
03.05.2022
What are the top 5 considerations to be aware of b...

Introduction: Brazil is a market of 210 million people Brazil is the largest country in South Americ...

Read more
Insider Insights
15.03.2022
NICE presents three-year international strategy

Two NICE teams (NICE International and the Science Policy and Research Programme) will act as key en...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.